Genematrix (109820.KQ) Stock Price

Genematrix Price

CLOSED
1,720.00
​
Market closed

Over the last 19 years Genematrix grew revenue by 12.7% annually, reaching 10.64 B KRW. Earnings per share have grown at 41.5% per year over the last 14 years. For Genematrix, the net margin of -17.2% is down versus -8.2% a few years ago.

Genematrix stock price

Access this data via the Eulerpool API

Genematrix business model & stock analysis

GENEMATRIX, Inc. engages in the development of platform and molecular diagnostics products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 61 full-time employees. The company went IPO on 2009-11-06. The firm operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.

Frequently asked questions about Genematrix

Converted at the current exchange rate, the Genematrix share trades at 1.14 EUR (1,720.00 KRW).

The revenue cannot currently be calculated for Genematrix.

The profit cannot currently be calculated for Genematrix.

The P/E ratio cannot be calculated for Genematrix at the moment.

The P/S cannot be calculated for Genematrix currently.

The Eulerpool Quality Score for Genematrix is 2/10.

The ISIN of Genematrix is KR7109820001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Genematrix is 109820.KQ. The ticker symbol is used to trade Genematrix shares on the stock exchange.

Fair ValueTerminal
1,651.20 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
174.48 M KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Nov 6, 2009
ISIN
KR7109820001
Cusip
Y26853104
Market capitalization
34.34 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.97
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-10.50 %
Last updated Oct 9, 2026, 12:20 PM

Genematrix Peer Group

Genematrix FIGI

109820:KS · BBG000PMKQ76109820:KQ · BBG000PMKR74

All fundamentals and in-depth analysis of Genematrix

Our stock analysis for Genematrix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genematrix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.